The antiviral drugs have helped inspire hope among senior administration officials that the United States will be able to curb the devastating toll from the Delta variant.
Tag: Drugs (Pharmaceuticals)
Pressure Grows on G20 Nations to Get Covid Vaccines to the Poor
The world’s leaders are focusing on preventing future pandemics, but experts say rich nations are not doing enough to help the poor survive the current one.
Merck Will Share Formula for Its Covid Pill With Poor Countries
The company announced a licensing deal that will allow the drug, molnupiravir, to be made and sold cheaply in 105 developing nations.
Iran Plans to Abandon One of Its Homegrown Covid Shots
The defense ministry said there was too little demand for its Fakhravac vaccine to justify producing it, and blamed the health ministry for reneging on promised orders.
Iran Plans to Abandon One of Its Homegrown Covid Shots
The defense ministry said there was too little demand for its Fakhravac vaccine to justify producing it, and blamed the health ministry for reneging on promised orders.
Gates Foundation Pledges $120 Million to Help Get Merck Covid Pills to Poor Countries
Regulatory hurdles and supply chain issues could slow efforts to produce generic versions of Merck’s antiviral molnupiravir for developing nations, despite licensing agreements.
Will New Covid Treatments Be as Elusive for Poor Countries as Vaccines?
Merck has taken a step to make its antiviral pill available in poor nations, but many obstacles remain for broad access to coronavirus drugs.
Asia-Pacific Countries Rush to Buy Merck Covid Pill
The home treatment, molnupiravir, is said by the company to potentially halve the risk of hospitalization and death from the virus.
Pfizer Booster Can Be Given After 6 Months, European Drug Agency Says
The European Medicines Agency also said that extra doses of the Moderna and Pfizer-BioNTech vaccines could be given to people with underlying health conditions as early as 28 days after a second dose.
W.H.O. Backs Antibody Treatment For High-Risk Covid Patients
The expensive treatment, developed by the U.S. drug maker Regeneron and the Swiss biotech company Roche, has garnered attention as backstop for those who shun vaccines.